INTRODUCTION AND OBJECTIVES: Upfront orchiectomy (OE) followed by systemic chemotherapy is the preferred treatment approach to metastatic non-seminomatous germ cell tumors (NSGCT). However, some patients present with advanced, symptomatic disease, necessitating prompt initiation of chemotherapy. We sought to examine survival characteristics and post-chemotherapy histopathologic findings of patients who underwent delayed OE.
METHODS: 453 patients who underwent post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) between 2000 and June 2018 were included. Delayed OE was performed in 67 of the 453 patients (15%). Retroperitoneal and primary site pathology were determined and concordance evaluated by chi-squared test. Logistic regression models were conducted to assess patient survival. RESULTS: Of the 67 patients who underwent delayed OE, 57 (85%) were clinical stage III. The delayed OE pathology was consistent with necrosis, viable germ cell tumor, and teratoma in 40 (60%), 8 (12%), and 19 (28%) patients, respectively. Median pathologic size of teratoma or viable tumor on delayed OE was 0.7 cm, of which 10 (37%) were 0.5 cm and 5 (19%) were 0.1 cm. PC-RPLND pathology showed necrosis, viable germ cell tumor, and teratoma in 32 (48%), 11 (16%), and 24 (36%) patients, respectively. Histopathology between delayed OE and RPLND was only concordant in 37 patients (55%, p<0.001) ( Table 1) . With a median follow-up of 4.2 years, delayed OE was associated with a shorter recurrence-free survival (RFS) compared to upfront OE (p[0.015), but had no effect on cancer-specific survival (CSS) or overall survival (OS). The presence of viable tumor in the testis after chemotherapy had no effect on RFS, CSS, or OS.
CONCLUSIONS: Acceptable oncologic outcomes can be achieved when upfront systemic chemotherapy is necessary for advanced, symptomatic NSGCT prior to orchiectomy. Orchiectomy is nonnegotiable, as many patients continue to harbor small amounts of residual teratoma and viable tumor despite normal clinical findings. . Only a few studies in some other tumor types have identified a limited set of genes, related to invasion, progression or metastases to be distinctly upregulated at the invasive tumor front in metastasized patients. However, systematic investigations are missing. Therefore, regional differences in the TGCT subtype seminomas were investigated to achieve a better understanding of the mechanisms involved in the metastatic process.
METHODS: Formalin-fixed paraffin embedded (FFPE) tissue samples of patients with clinical stage I disease, no adjuvant therapy and a relapse-free survival of at 2 years (n [ 21), and patients showing metastasis (n [ 14) were selected for the study. The tumor front (TF) and tumor center (TC) regions of each patient were determined and separately collected using laser capture microdissection. RNA was extracted and a multiplex gene expression analysis was performed on all TF and TC samples using nCounter technology of Nanostring. A panel of 770 transcripts was analyzed using the PanCancer Progression panel. Different bioinformatics tools were employed for analyzing the expression data.
RESULTS: Differential gene expression patterns were observed in the metastatic and non-metastatic patients, with respect to both the tumor front and tumor center regions. Ingenuity pathway analysis on the differentially expressed genes showed enrichment of tumor functions like migration, invasion, and angiogenesis at the TF as compared to the TC. Remarkably, prominent inflammatory and cancer related pathways such as IL-6 signaling, acute phase response signaling, NF-kB signaling and, dendritic cell maturation were significantly upregulated in the metastatic versus non-metastatic tumors (z-score > AE 2 and p-value < 0.05).
CONCLUSIONS: This is the first study showing tumor heterogeneity in TGCTs. Evidently, IL-6 signalling was the most significantly upregulated pathway in the metastatic versus the non-metastatic patients, that could serve as a therapeutic target for personalized therapy.
